Ryse Health is a technology company.
Ryse Health has raised $7.0M across 1 funding round.
Ryse Health has raised $7.0M in total across 1 funding round.
Ryse Health is a healthcare technology company specializing in Type 2 diabetes management for patients with complex cases, particularly those with A1C levels above 8%.[1][2][5] It builds a hybrid care platform combining in-person clinics in Arlington, VA, and Baltimore, MD, with virtual tech-enabled support, including continuous glucose monitors (CGMs), a custom app for real-time data and self-management, and personalized plans from a multidisciplinary team of endocrinologists, diabetes educators, dietitians, behavioral therapists, and health coaches.[1][2][3][4] This solves the shortcomings of traditional primary care, specialty care, and virtual-only models by delivering up to 50% better outcomes, such as a 2-point average HbA1c drop in 90 days and 36% reduction in elevated blood sugars after 60 days, while serving 440 patients (mostly under 65) with high patient satisfaction (4.95/5 rating).[1][3][5] The company has raised $3.4M in seed funding and $6.5M in Series A led by Route 66 Ventures, fueling clinic expansion and partnerships like CareFirst BlueCross BlueShield.[1][3][5]
Ryse Health was co-founded in 2020-2021 by CEO Richard Gurley, a healthcare executive with prior leadership at Evolent Health and WelbeHealth plus advisory roles in growth companies, and CMO Dr. Erin Kane, a Harvard- and Johns Hopkins-trained physician who led initiatives like the Hopkins Capacity Command Center and a GW COVID-19 monitoring program.[2][3] The idea emerged from Gurley's recognition that existing care models—primary, specialty, or virtual—fail chronic disease patients like those with Type 2 diabetes, prompting a "blank slate" redesign for tailored, efficient management.[2] Early traction included joining CareFirst's incubation program in 2022, initial clinical results showing rapid A1c improvements, and seed funding in 2023, building to the 2024 Series A amid growing demand for hybrid care proven effective during the pandemic.[1][2][3][5]
Ryse Health rides the wave of digital health innovation in chronic disease management, particularly Type 2 diabetes affecting millions amid rising obesity and aging populations, amplified by post-pandemic hybrid care validation.[5] Timing aligns with advances like non-invasive CGMs (e.g., Apple's developments) and value-based contracts favoring outcomes over volume, positioning Ryse to scale via employer deals and insurers like CareFirst.[1][5] Market forces include demand for interdisciplinary, tech-backed models reducing complications (blindness, kidney failure at high A1c) and costs, as studies show hybrid approaches maintain health better than in-person alone.[5] It influences the ecosystem by pioneering efficient diabetes care from DC to Baltimore, potentially expanding nationally and inspiring integrated platforms for other chronics.[1][2]
Ryse Health is primed to accelerate with Series A funds, targeting clinic growth, partner networks, and value-based contracts by year-end to serve thousands beyond its current 440 patients.[1][5] Trends like AI-enhanced CGMs, broader telehealth reimbursement, and diabetes reversal focus will propel it, evolving from local specialist to national leader in hybrid endocrinology. As hybrid models prove essential for complex chronics, Ryse's superior outcomes position it to redefine Type 2 care, changing lives one personalized plan at a time—much like its founding vision to beat diabetes where others fall short.[1][2]
Ryse Health has raised $7.0M in total across 1 funding round.
Ryse Health's investors include Accel, Citi Ventures, Insight Partners, Mouro Capital, Point72 Ventures, Route 66 Ventures.
Ryse Health has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $7.0M Series A | Accel, Citi Ventures, Insight Partners, Mouro Capital, Point72 Ventures, Route 66 Ventures |